Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Cai

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
International Journal of Molecular Sciences|December 11, 2022
Sustainable Plant-Based Biopolymer Membranes for PEM Fuel CellsSongtao Li, George Cai, Songze Wu, et al.
Cell Systems|June 22, 2023
BioAutoMATED: An end-to-end automated machine learning tool for explanation and design of biological sequencesJacqueline A Valeri, Luis R Soenksen, Katherine M Collins, et al.
Lancet (London, England)|June 5, 2025
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trialLuis Paz-Ares, Hossein Borghaei, Stephen V Liu, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
International Journal of Molecular Sciences|December 11, 2022
Sustainable Plant-Based Biopolymer Membranes for PEM Fuel CellsSongtao Li, George Cai, Songze Wu, et al.
Cell Systems|June 22, 2023
BioAutoMATED: An end-to-end automated machine learning tool for explanation and design of biological sequencesJacqueline A Valeri, Luis R Soenksen, Katherine M Collins, et al.
Lancet (London, England)|June 5, 2025
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trialLuis Paz-Ares, Hossein Borghaei, Stephen V Liu, et al.
Pageof 2